Improving the distribution of Doxil® in the tumormatrix by depletion of tumor hyaluronan

Journal of Controlled Release

Volumn 191, Issue , 2014, Pages 105-114

  Kohli, Aditya G ^a,b   Kivimäe, Saul ^b   Tiffany, Matthew R ^b   Szoka, Francis C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Extra cellular matrix; Liposomes; Tumor penetration

Indexed keywords

BIOCHEMISTRY; BLOOD VESSELS; LIPOSOMES; TUMORS;

BREAST CANCER; COLOCALIZATION ANALYSIS; ENCAPSULATED DRUGS; EXTRACELLULAR MATRICES; GLYCOSAMINOGLYCANS; HIGH MOLECULAR WEIGHT; NON-UNIFORM DISTRIBUTION; TUMOR PENETRATION;

HYALURONIC ACID;

DOXORUBICIN; GLUCURONIC ACID; GLYCOSAMINOGLYCAN; HYALURONIC ACID; HYMECROMONE; LIPOSOME; PRODRUG; ANTINEOPLASTIC ANTIBIOTIC; MACROGOL DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; HISTOCHEMISTRY; MACROPHAGE; METASTASIS; MOLECULAR WEIGHT; MONOTHERAPY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PHAGOCYTE; PHOSPHORYLATION; PRIORITY JOURNAL; SOLID TUMOR; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DEFICIENCY; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MAMMARY NEOPLASMS, EXPERIMENTAL; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; SOLUBILITY; TIME; TUMOR CELL LINE;

ADMINISTRATION, ORAL; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; DOXORUBICIN; FEMALE; HYALURONIC ACID; HYMECROMONE; INJECTIONS, INTRAVENOUS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE, INBRED BALB C; PHOSPHORYLATION; POLYETHYLENE GLYCOLS; PRODRUGS; SOLUBILITY; TIME FACTORS; TUMOR MICROENVIRONMENT;

EID: 84906951532     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.05.019     Document Type: Article

References (62)

1. T.M. Allen, P.R. Cullis, Liposomal drug delivery systems: from concept to clinical applications, Adv. Drug Deliv. Rev. 65 (2013) 36-48.
2. M.J. Ernsting, M. Murakami, A. Roy, S.-D. Li, Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles, J. Control. Release 172 (2013) 782-794.
3. R.K. Jain, T. Stylianopoulos, Delivering nanomedicine to solid tumors, Nat. Rev. Clin. Oncol. 7 (2010) 653-664.
4. A.I. Minchinton, I.F. Tannock, Drug penetration in solid tumours, Nat. Rev. Cancer 6 (2006) 583-592.
5. C.-H. Heldin, K. Rubin, K. Pietras, A. Ostman, High interstitial fluid pressure - An obstacle in cancer therapy, Nat. Rev. Cancer 4 (2004) 806-813.
6. K.N. Sugahara, T. Teesalu, P.P. Karmali, V.R. Kotamraju, L. Agemy, D.R. Greenwald, et al., Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs, Science 328 (2010) 1031-1035.
7. E.E. Paoli, E.S. Ingham, H. Zhang, L.M. Mahakian, B.Z. Fite, M.K. Gagnon, et al., Accumulation, internalization and therapeutic efficacy of neuropilin-1-targeted liposomes, J. Control. Release 178 (2014) 108-117.
8. H. Gao, Z. Yang, S. Zhang, S. Cao, Z. Pang, X. Yang, et al., Glioma-homing peptide with a cell-penetrating effect for targeting delivery with enhanced glioma localization, penetration and suppression of glioma growth, J. Control. Release 172 (2013) 921-928.
9. S.Wang, I.S. Shin, H.Hancock, B.-S. Jang, H.-S. Kim, S.M. Lee, et al., Pulsedhigh intensity focused ultrasound increases penetration and therapeutic efficacy of monoclonal antibodies in murine xenograft tumors, J. Control. Release 162 (2012) 218-224.
10. L. Li, T.L.M. ten Hagen, M. Bolkestein, A. Gasselhuber, J. Yatvin, G.C. van Rhoon, et al., Improved intratumoral nanoparticle extravasation and penetration by mild hyperthermia, J. Control. Release 167 (2013) 130-137.
11. C. Wong, T. Stylianopoulos, J. Cui, J. Martin, V.P. Chauhan, W. Jiang, et al., Multistage nanoparticle delivery system for deep penetration into tumor tissue, Proc. Natl. Acad. Sci. U. S. A. 108 (2011) 2426-2431.
12. W. Mok, Y. Boucher, R.K. Jain, Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus, Cancer Res. 67 (2007) 10664-10668.
13. K.P. Olive, M.A. Jacobetz, C.J. Davidson, A. Gopinathan, D. McIntyre, D. Honess, et al., Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer, Science 324 (2009) 1457-1461.
14. B. Diop-Frimpong, V.P. Chauhan, S. Krane, Y. Boucher, R.K. Jain, Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors, Proc. Natl. Acad. Sci. U. S. A. 108 (2011) 2909-2914.
15. T.D.McKee, P.Grandi, W.Mok, G. Alexandrakis, N. Insin, J.P. Zimmer, et al., Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector, Cancer Res. 66 (2006) 2509-2513.
16. J. Liu, S. Liao, B. Diop-Frimpong, W. Chen, S. Goel, K. Naxerova, et al., TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma, Proc. Natl. Acad. Sci. U. S. A. 109 (2012) 16618-16623.
17. T. Roy Chaudhuri, R.D. Arnold, J. Yang, S.G. Turowski, Y. Qu, J.A. Spernyak, et al., Mechanisms of tumor vascular priming by a nanoparticulate doxorubicin formulation, Pharm. Res. 29 (2012) 3312-3324.
18. C.V. Pastuskovas, E.E. Mundo, S.P.Williams, T.K. Nayak, J. Ho, S.Ulufatu, et al., Effects of anti-VEGF on pharmacokinetics, biodistribution and tumor penetration of trastuzumab in a preclinical breast cancer model, Mol. Cancer Ther. 11 (2012) 752-762.
19. V.P. Chauhan, T. Stylianopoulos, J.D.Martin, Z. Popovic, O. Chen, W.S. Kamoun, et al., Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner, Nat. Nanotechnol. 7 (2012) 383-388.
20. H. Maeda, G.Y. Bharate, J. Daruwalla, Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect, Eur. J. Pharm. Biopharm. 71 (2009) 409-419.
21. F. Yuan, M. Leunig, S.K.Huang, D.A. Berk, D. Papahadjopoulos, R.K. Jain, Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft, Cancer Res. 54 (1994) 3352-3356.
22. R.T. Pirinen, R.H. Tammi, M.I. Tammi, P.K. Pääkkö, J.J. Parkkinen, U.M. Agren, et al., Expression of hyaluronan in normal and dysplastic bronchial epithelium and in squamous cell carcinoma of the lung, Int. J. Cancer 79 (1998) 251-255.
23. K. Ropponen, M. Tammi, J. Parkkinen, M. Eskelinen, R. Tammi, P. Lipponen, et al., Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer, Cancer Res. 58 (1998) 342-347.
24. L.P. Setälä, M.I. Tammi, R.H. Tammi, M.J. Eskelinen, P.K. Lipponen, U.M. Agren, et al., Hyaluronan expression in gastric cancer cells is associated with local and nodal spread and reduced survival rate, Br. J. Cancer 79 (1999) 1133-1138.
25. M.A. Anttila, R.H. Tammi, M.I. Tammi, K.J. Syrjänen, S.V. Saarikoski, V.M. Kosma, High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer, Cancer Res. 60 (2000) 150-155.
26. P. Auvinen, R. Tammi, J. Parkkinen, M. Tammi, U. Agren, R. Johansson, et al., Hyaluronan in peritumoral stroma andmalignant cells associateswith breast cancer spreading and predicts survival, Am. J. Pathol. 156 (2000) 529-536.
27. D. Mahadevan, D.D. Von Hoff, Tumor-stroma interactions in pancreatic ductal adenocarcinoma, Mol. Cancer Ther. 6 (2007) 1186-1197.
28. M.H. Shepard, G.I. Frost, M.E. Rybak, R.K. Ramanathan, D.D. Von Hoff, J. Infante, et al., Targeting hyaluronan (HA) in the tumor stroma. Translational evaluation of pegylated hyaluronidase (PEGPH20) in animal models and patients with advanced solid tumors, EORTC, Florida, 2010. (1-1).
29. M.E. Mummert, D.I. Mummert, L. Ellinger, A. Takashima, Functional roles of hyaluronan in B16-F10 melanoma growth and experimental metastasis in mice, Mol. Cancer Ther. 2 (2003) 295-300.
30. E. Arai, Y. Nishida, J. Wasa, H. Urakawa, L. Zhuo, K. Kimata, et al., Inhibition of hyaluronan retention by 4-methylumbelliferone suppresses osteosarcoma cells in vitro and lung metastasis in vivo, Br. J. Cancer 105 (2011) 1839-1849.
31. Z. Pályi-Krekk, M. Barok, J. Isola, M. Tammi, J. Szöllosi, P. Nagy, Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer, Eur. J. Cancer 43 (2007) 2423-2433.
32. C.B. Thompson, H.M. Shepard, P.M. O'Connor, S. Kadhim, P. Jiang, R.J. Osgood, et al., Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models, Mol. Cancer Ther. 9 (2010) 3052-3064.
33. V.B. Lokeshwar, L.E. Lopez, D. Munoz, A. Chi, S.P. Shirodkar, S.D. Lokeshwar, et al., Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells, Cancer Res. 70 (2010) 2613-2623.
34. K. Beckenlehner, S. Bannke, T. Spruss, G. Bernhardt, H. Schönenberg, W. Schiess, Hyaluronidase enhances the activity of adriamycin in breast cancer models in vitro and in vivo, J. Cancer Res. Clin. Oncol. 118 (1992) 591-596.
35. P.P. Provenzano, C. Cuevas, A.E. Chang, V.K. Goel, D.D. Von Hoff, S.R. Hingorani, Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma, Cancer Cell 21 (2012) 418-429.
36. L. Eikenes, Ø.S. Bruland, C. Brekken, C. de L. Davies, Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts, Cancer Res. 64 (2004) 4768-4773.
37. T. Hiraga, S. Ito, H. Nakamura, Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production, Cancer Res. 73 (2013) 4112-4122.
38. H. Okuda, A. Kobayashi, B. Xia, M. Watabe, S.K. Pai, S. Hirota, et al., Hyaluronan synthase HAS2 promotes tumor progression in bone by stimulating the interaction of breast cancer stem-like cells with macrophages and stromal cells, Cancer Res. 72 (2012) 537-547.
39. S. Twarock, T. Freudenberger, E. Poscher, G. Dai, K. Jannasch, C. Dullin, et al., Inhibition of oesophageal squamous cell carcinoma progression by in vivo targeting of hyaluronan synthesis, Mol. Cancer 10 (2011) 30.
40. S. Yoshihara, A. Kon, D. Kudo, H. Nakazawa, I. Kakizaki, M. Sasaki, et al., A hyaluronan synthase suppressor, 4-methylumbelliferone, inhibits liver metastasis of melanoma cells, FEBS Lett. 579 (2005) 2722-2726.
41. D.Kudo, A. Kon, S. Yoshihara, I. Kakizaki, M. Sasaki, M. Endo, et al., Effectofahyaluronan synthase suppressor, 4-methylumbelliferone, on B16F-10melanoma cell adhesion and locomotion, Biochem. Biophys. Res. Commun. 321 (2004) 783-787.
42. H. Nakazawa, S. Yoshihara, D. Kudo, H. Morohashi, I. Kakizaki, A. Kon, et al., 4- methylumbelliferone, a hyaluronan synthase suppressor, enhances the anticancer activity of gemcitabine in human pancreatic cancer cells, Cancer Chemother. Pharmacol. 57 (2006) 165-170.
43. H. Morohashi, A. Kon, M. Nakai, M. Yamaguchi, I. Kakizaki, S. Yoshihara, et al., Study of hyaluronan synthase inhibitor, 4-methylumbelliferone derivatives on human pancreatic cancer cell (KP1-NL), Biochem. Biophys. Res. Commun. 345 (2006) 1454-1459.
44. M.J. Zamek-Gliszczynski, K.-I. Nezasa, X. Tian, J.C. Kalvass, N.J. Patel, T.J. Raub, et al., The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice, Mol. Pharmacol. 70 (2006) 2127-2133.
45. V. Uchaipichat, P.I.Mackenzie, X.-H. Guo, D. Gardner-Stephen, A. Galetin, J.B.Houston, et al., Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4- methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid, Drug Metab. Dispos. 32 (2004) 413-423.
46. A. Abate, V. Dimartino, P. Spina, P.L. Costa, C. Lombardo, A. Santini, et al., Hymecromone in the treatment of motor disorders of the bile ducts: A multicenter, double-blind, placebo-controlled clinical study, Drugs Exp. Clin. Res. 27 (2001) 223-231.
47. E.R. Garrett, J. Venitz, K. Eberst, J.J. Cerda, Pharmacokinetics and bioavailabilities of hymecromone in human volunteers, Biopharm. Drug Dispos. 14 (1993) 13-39.
48. I.P. Kostova, I.I. Manolov, I.N. Nicolova, N.D. Danchev, New metal complexes of 4- methyl-7-hydroxycoumarin sodium salt and their pharmacological activity, Farmaco 56 (2001) 707-713.
49. A. Kultti, S. Pasonen-Seppänen, M. Jauhiainen, K.J. Rilla, R. Kärnä, E. Pyöriä, et al., 4- Methylumbelliferone inhibits hyaluronan synthesis by depletion of cellular UDPglucuronic acid and downregulation of hyaluronan synthase 2 and 3, Exp. Cell Res. 315 (2009) 1914-1923.
50. B.J. Crielaard, S. van der Wal, H.T. Le, A.T.L. Bode, T. Lammers, W.E. Hennink, et al., Liposomes as carriers for colchicine-derived prodrugs: vascular disrupting nanomedicines with tailorable drug release kinetics, Eur. J. Pharm. Sci. 45 (2012) 429-435.
51. A.G. Kohli, H.M. Kieler-Ferguson, D. Chan, F.C. Szoka, A robust and quantitative method for tracking liposome contents after intravenous administration, J. Control. Release 176 (2014) 86-93.
52. K. Tao, M. Fang, J. Alroy, G.G. Sahagian, Imagable 4T1 model for the study of late stage breast cancer, BMC Cancer 8 (2008) 228.
53. A. Naba, K.R. Clauser, S. Hoersch, H. Liu, S.A. Carr, R.O. Hynes, The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices, Mol. Cell. Proteomics 11 (2012) (M111.014647).
54. J.W. Baish, T. Stylianopoulos, R.M. Lanning, W.S. Kamoun, D. Fukumura, L.L. Munn, et al., Scaling rules for diffusive drug delivery in tumor and normal tissues, Proc. Natl. Acad. Sci. U. S. A. 108 (2011) 1799-1803.
55. P.P. Provenzano, S.R. Hingorani, Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer, Br. J. Cancer 108 (2013) 1-8.
56. L. Eikenes, M. Tari, I. Tufto, Ø.S. Bruland, C. de Lange Davies, Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx™) in human osteosarcoma xenografts, Br. J. Cancer 93 (2005) 81-88.
57. D. Jiang, J. Liang, P.W. Noble, Hyaluronan in tissue injury and repair, Annu. Rev. Cell Dev. Biol. 23 (2007) 435-461.
58. L. Jadin, L.H. Bookbinder, G.I. Frost, A comprehensive model of hyaluronan turnover in the mouse, Matrix Biol. 31 (2012) 81-89.
59. W. Lin, S. Shuster, H.I. Maibach, R. Stern, Patterns of hyaluronan staining are modified by fixation techniques, J. Histochem. Cytochem. 45 (1997) 1157-1163.
60. J. Schindelin, I. Arganda-Carreras, E. Frise, V.Kaynig, M. Longair, T.Pietzsch, etal., Fiji: An open-source platform for biological-image analysis, Nat. Methods 9 (2012) 676-682.
61. E. Manders, F.J. Verbeek, J.A. Aten, Measurement of co-localization of objects in dualcolour confocal images, J. Microsc. 169 (1993) 375-382.
62. J.P. Feldman, R. Goldwasser, S. Mark, J. Schwartz, I. Orion, Amathematicalmodel for tumor volume evaluation using two-dimensions, J. Appl. Quant. Methods 4 (2009) 455-462.